have you looked at the teva chart lately? >> no. >> you're going lie. >> he was doing well and it collapsed. there's so much vile here. there's no direction. i would say just try something else. >> well, this is the thing if -- it's a situation that you're looking for it to bounce around here. that's when you're going get paid on the trade. that's what you're doing. >> scott asked are you buying long s&p puts ahead to come a disaster? >> well, i would not be looking to buy for the long run. index, etf options and prices are really high right now. it does not look that high when you're looking at amazon, but it's really high. it's hard to make the money directional here. if you're looking to protect it in the near term, you may want to look to do spreads. buy one and sell another one. >> yeah, that's true. what is happening is that all of this has the panic. they have raced out and that's the reason that the price is as high as tsz. >> time for the final call for the options pit. >> yeah, they can bet on the gold whether you l

it haunted teva mccarthy. publicly, he projected the appearance of a man who will be the next speaker. but in private, his allies told him the pursuit of power was changing them. he said that even if he won, he cannot govern. we need someone to get us to 247, referring to the total number of house republicans. and i was never going to get to 247. we would take your phone calls and see what you think about the situation in the house, and the republican leadership there. give us a call, let us know what you think. orson is a tweet @cspan. can also get on facebook. some members wanted to proceed and vote on webster or chaffetz. forjordan was ready to run leader if mccarthy won. and then we hear from ryan costello, he actually broke the news about mccarthy. apparently i broke the news. blame it on being a freshman and going up the wrong door. he was the first one we heard earlier today that let us know kevin mccarthy was not going to be running for speaker. we would take a look at what commerzbank costello said an

finally, a lot of questions about teva's biggest drug for multiple sclerosis. it is facing generic competition. a lot of encouraging signs about being able to keep patient os o that drug. >> let's have a look at the earning's scorecard. 60% of the s&p 500 firms reported thus far, 73% are above estimates. 7% hit them right on the number and 20% missed estimates. and that does it for the earnings squad. >> we're going to keep talking about earnings. shares of mate yacht are under pressure despite beating profit estimates. revenue growth was weaker than expected. the hotel owner offering soft guidance. so what is ahead for marriott and the entire industry? simon hobbs with marriott's ceo in an exclusive. >> let's take you away. arnie, good to see you again. >> simon, how are you? >> there you are. how would you sum up the quarter? >> i think it was a solid quarter. i don't think it was a spectacular quarter. i think if folks were looking for this quarter to come out and show the u.s. economy was growing at 4% or 5%, they would have been disappointed. maybe there i

. >> i think the home run is teva. it is trading in the 50s. and they are buying the generic from allergan. i think december is the date they will come out with the financing financing. after that is established, they will pay down debt and acquire more assets. i think this stock that could work to 100 easily over the next four months. >> remember the teva sandals. >> not the same. >> but i remember i have an image of dave wearing the sandals. >> that would be a good image. >> my home run pick general electric. g.e. we talk about solar stocks but they make the pieces that go into the solar things and if you want to build a fast electric train, you have to talk to ge. you buy it. home run. >> you need to believe the energy sector is going to pick up don't you. >> not necessarily. >> they sell a lot of turbines. >> but they sell other things too. so this is a long-term home run play. >> okay. gee. >> i love the crack of the bat. >> you like that. can't spell home run without allergan, people. check it out. h.e.n. and we talked when the valeant th

. >> have you looked at the teva chart lately? >> no. it was doing quite well. it collapsed. there is so much vol here. there thing has no direction. i would say try something else. >> this is the thing. a buy right is a situation where you are looking for it to bounce around. that is when you'll get paidond trade and that is the trade we're making. >> next tweet. scott asks are you buying long dates spy puts as a way to hedge in case of coming earnings disaster, dan? >> i wouldn't look to buy long if i was looking at the near term. edx is high right now it. doesn't look high when you look at amazon implied vol but it is really high so it is hard to make money directionally here so i think if you are looking to protect your portfolio in the near term, you may want to look to do spreads. buy one put and sell another downside put. >> that is true. what is happening is all of this has initiated panic and people bid up because they raced out and bought the puts and that is the reason the price is as high as it is. >> and time for the final cart. carter braxton worth. >> you like

finally this summer he agreed to sell allergan's general ericks business to teva for about $40 billion. so why does this make allergan a target for pfizer? the new york-based drug giant has been looking for a way to lower its corporate tax rate. with allergan in ireland, pfizer could pursue an inversion deal, moving its headquarters overseas. and though the move would be bound to draw political scrutiny, analysts at bernstein estimate it could take pfizer's tax rate down from about 25% to 18%. an overseas deal would also let pfizer tap into its cash held outside the u.s. about 2/3 of its $30 billion horde. and analysts say it would strengthen the so-called innovative products part of pfizer's business. for a potential split of the company in a couple years. not to mention blockbuster drugs in botox and alzheimer's treatment namenda. some wonder if it's an especially good time for dealmaking in the drug world with valuations depressed in the last few months. >> we've seen lots of negative sentiment on drug prices, on pricing for drugs andgs biotech products. that's created some pressure

billion cash check in stock in the first quarter because it is selling its generic drug business to teva to give more options to the shareholders when it comes to making money. each time takes a good company and makes it better it would be amazing if pfizer bought stock went out 308. it did hit my initial $100 price i set. when it was selling at $60. best thing to do is wait for the market to give you a better entry point. started today the stock was hurt badly even though it is an amazing company it's a rich stock. we also heard about stock not that cheap but going down a lot, whole foods, to me wfn if i were running the show i would take it private. the group is falling out of favor. if you want to buy wait until after the quarter. still more expensive than kroger, that's my favorite however, just under $30 might be close not yet. this industry needs to have whole foods the company to put them all together. thursday it's all about disney. disney's worked back to nearly 114. my take is you buy disney where it gets hammered. it makes a good case for itself. it bought back a gigantic amou

billion cash check in stock in the first quarter because it is selling its generic drug business to teva to give more options to the shareholders when it comes to making money. each time takes a good company and makes it better it would be amazing if pfizer bought allergan. however, just under $30 might be close not yet. this industry needs to have whole foods the company to put them all together. thursday it's all about disney. disney's worked back to nearly 114. my take is you buy disney where it gets hammered. it makes a good case for itself. it bought back a gigantic amount of stock in the interim. i would never take other side of a trade two quarters in row he's the ceo. we also heard from celgene. to me this might be the quarter where we hear something about rocepto it was recently required by celgene, a very inexpensive stock on 2017 numbers which is how you value bioteches in what is known as the out years. friday it will be all day fed talk. this is what i do, i put head phones and listen to joc jams. the curious statement from the feds could be in a simple phrase. if employment

when you get the money from teva, you can buy another company. the teva money, $40 million. balance sheet, crystal clear. nothing. >> when they get that deal gone. the stock is up. david, this isn't the folcrum of where we are right now. this is not involving great drugs. it is not what they want. >> the wave of inversions that already took place before the changes from treasury made it more difficult changed the landscape for so many companies in terms of their competitive position. if you have a competitor that has access to cash they have earned overseas, because they are no longer u.s. tax jurisdiction. that changes what they can do and their flexibility. it has been an unrelented focus of ian reed, the man that runs pfizer, sort of ahablike. >> he has one of the great wonder drugs of the year, lyrica, if you have nerve damage. it is not just amgen that has new drugs. we have new drugs. >> if you are going to structure this deal, it would likely have to be an all stock transaction that would result in 40% of ownership by allergan share holders of the combination. if you

he is getting $40 billion from teva, balance sheet. >> it is a different story lumped in in part becauseis well owned by hedge funds, many of whom believe that it is better to get out. the momentum had stalled and the overall strategy of acquiring, acquiring, acquiring, may be mitigated as a result of the stock being down so much. >> i hesitate to play devil's advocate, because i have not been a fan of value. >> understood. the cash flow at one point. this is a real company. he used the term enron, citron. enron is thermonuclear. >> i remember enron. i remember this does not seem the same. that said, the quality of the earnings certainly has to come in. >> the cash flow is real. >> it is real and the p.e. multiple is extraordinarily low. >> this morning, jim, you have bmo. they have been bullish on this stock for a long time. you cannot defend the specialty pharmacy structure. they downed the stock. >> that's why it is down about 7%, 8%. >> it goes back to the specialty pharmacies where they ship the product and work the unsureers. as much as 10% come from the specialty pharmacies. we ca

teva pharmaceuticals is considering a stock sale.heferrari are first day of trading at the new york stock exchange. the majority shareholder, cr chrysler sold a 9% share. >> the most important thing to me is i think we have treated shareholders in a way which i think was long overdue. asset that defines for ari pure automotive, perhaps it is a exaggeration. this is not really a car, this is a unique expression of art and technology. furry race almost $99 in their initial public offering. you can always get more business news at bloomberg.com. lessig a look at the european market close. it was a mixed day. we will head to london where ryan chilcote is standing by. ryan chilcote: a real mixture of green and red. and evenly fought battle between the optimist and pessimist. you can see that geographically here in europe. most of the polls are in germany ls are in germany. the postal service that they would raise their prices stands next year. sharesy, fiat chrysler -- the parent company of ferrari fell by almost 5.5% today. why -- as you

teva pharmaceutical has agreed to buy rimsa.of the strategy to grow in emerging markets. james bell has been elected to the board of directors, the move boosted apple's directors. cook says that he brings a wealth of global and financial experience. next half hour, auto sales are at the highest level in a decade. we will look at which company scored the highest gains. we will look into volkswagen and glencore, and we will preview tomorrow's jobs report. politics, bernie sanders is closing in on hillary clinton in the poll, but he is pulling in the cash. let's start with the democrats. has arstand sanders broader base of supporters that secretary clinton does. >> who is giving is very clear. bernie sanders passed the one million mark in terms of individual donations. grassroots donors. hillary clinton is winning the money battle. she has brought in $75 million. at her targets are high dollar donors. that is what led her to the $20 million this quarter, $47 million last corner. she goes for the traditional fundraising technique. b